

Petition for *Inter Partes Review* of
U.S. Patent No. 9,593,066 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LIQUIDIA TECHNOLOGIES, INC.,

Petitioner

v.

UNITED THERAPEUTICS CORPORATION,

Patent Owner

U.S. Patent No. 9,593,066

Issue Date: March 14, 2017

Title: Process to Prepare Treprostinil, the Active Ingredient in Remodulin®

~~DECLARATION OF JEFFREY D. WINKLER, PH.D.~~
~~IN SUPPORT OF~~ PETITION FOR *INTER PARTES* REVIEW
OF U.S. Patent No. 9,593,066

IPR2020-00769

~~VI. IV. SUMMARY OVERVIEW OF THE '066 PATENT~~

A. Brief Description of the '066 Patent

~~I understand that the~~ The '066 patent is entitled “Process to Prepare Treprostinil, the Active Ingredient in Remodulin®.” The claims of the '066 patent are product-by-process claims. These claims include two independent (claims 1 and 8) and eight dependent claims.


The '066 patent discloses an “improved process” to prepare prostacyclin derivatives such as treprostinil. (Ex. 1001, Abstract.) Claim 1 is drawn to a pharmaceutical composition comprising treprostinil or a pharmaceutically acceptable salt thereof. Claim 8 is drawn to a process of preparing the same product from claim 1, comprising the steps of alkylation of an intermediate triol ~~and hydrolyzing~~ to form a treprostinil ~~or a pharmaceutically acceptable salt thereof~~. (*Id.*, claims 1 and 8.)

Each of the independent claims include limitations that the claimed pharmaceutical composition/~~product~~ is made by a process comprising: (a) providing a starting batch of treprostinil having one or more impurities resulting from prior alkylation and hydrolysis steps; (b) forming a treprostinil salt by adding a base; and (c) preparing a pharmaceutical composition/~~product~~ comprising treprostinil or a pharmaceutically acceptable salt thereof from the isolated treprostinil salt.

~~The claim limitations of the '066 patent are as follows:~~


	Claim Limitation
1 [a]	A pharmaceutical composition comprising treprostinil or a pharmaceutically acceptable salt thereof,
1 [b]	said composition prepared by a process comprising:
1 [c]	providing a starting batch of treprostinil having one or more impurities resulting from prior alkylation and hydrolysis steps,
1 [d]	forming a salt of treprostinil by combining the starting batch and a base,

IPR2020-00769

1 [e]	isolating the treprostnil salt, and
1 [f]	preparing a pharmaceutical composition comprising treprostnil or a pharmaceutically acceptable salt thereof from the isolated treprostnil salt,
1 [g]	whereby a level of one or more impurities found in the starting batch of treprostnil is lower in the pharmaceutical composition, and
1 [h]	wherein said alkylation is alkylation of benzindene triol.
2	The pharmaceutical composition of claim 1, wherein the salt is isolated in crystalline form.
3	The pharmaceutical composition of claim 1, wherein the base is selected from the group consisting of sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, and choline.
4	The pharmaceutical composition of claim 3, wherein the base is diethanolamine.
5	The pharmaceutical composition of claim 1, wherein the base is combined with treprostnil that has not been previously isolated.
6	The pharmaceutical composition of claim 1, wherein the isolated salt is stored at ambient temperature.
7	The pharmaceutical composition of claim 1, which is a pharmaceutical solution.
8[a]	A process of preparing a pharmaceutical product comprising treprostnil or a pharmaceutically acceptable salt thereof, comprising:
8[b]	Alkylating a triol intermediate of the formula: 
8[c]	hydrolyzing the resulting compound to form treprostnil,
8[d]	forming a salt of treprostnil stable at ambient temperature,
8[e]	storing the treprostnil salt at ambient temperature, and
8[f]	preparing a pharmaceutical product from the treprostnil salt after storage,
8[g]	wherein the pharmaceutical product comprises treprostnil or a pharmaceutically acceptable salt thereof
9	A pharmaceutical product prepared by the process of claim 8.
10	The process as claimed in claim 8, wherein forming the salt of treprostnil stable at ambient temperature is performed by adding diethanolamine to treprostnil.

IPR2020-00769

The [More specifically, the](#) '066 patent discloses a process for the preparation of a compound of Formula I (which includes treprostinil) shown below:




(Ex. 1001 at col. 2:7-21), ~~where.~~ [Where:](#) $w = 1, 2, \text{ or } 3$; Y_1 is trans-CH=CH- , cis-CH=CH- , $\text{—CH}_2(\text{CH}_2)_m\text{—}$, or $\text{—C}\equiv\text{C—}$; m is $1, 2, \text{ or } 3$; M_1 is $\alpha\text{-OH}$; $\beta\text{-R}_5$ or $\alpha\text{-R}_5$; $\beta\text{-OH}$ or $\alpha\text{-OR}_2$; $\beta\text{-R}_5$ or $\alpha\text{-R}_5$; $\beta\text{-OR}_2$, wherein R_5 is hydrogen or methyl, R_2 is an alcohol protecting group; L_1 is $\alpha\text{-R}_3$; $\beta\text{-R}_4$, $\alpha\text{-R}_4$; $\beta\text{-R}_3$, or a mixture of $\alpha\text{-R}_3$; $\beta\text{-R}_4$ and $\alpha\text{-R}_4$; $\beta\text{-R}_3$, wherein R_3 and R_4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R_3 and R_4 is fluoro only when the other is hydrogen or fluoro; and R_7 is (1) $\text{—C}_p\text{H}_{2p}$, CH_3 , wherein p is an integer from 1 to 5 inclusive, (2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, $(\text{C}_1\text{-C}_3)\text{alkyl}$, or $(\text{C}_1\text{-C}_3)\text{alkoxy}$, with the proviso that not more than two substituents are other than alkyl, with the proviso that R_7 is phenoxy or substituted phenoxy, only when R_3 and R_4 are hydrogen or methyl, being the same or different, (3) phenyl, benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, $(\text{C}_1\text{-C}_3)\text{alkyl}$, or $(\text{C}_1\text{-C}_3)\text{alkoxy}$, with the proviso that not more than two substituents are other than alkyl, (4) $\text{cis-CH=CH—CH}_2\text{—CH}_3$, (5) $\text{—(CH}_2)_2\text{—CH(OH)—CH}_3$, or (6) $\text{—(CH}_2)_3\text{—CH=C(CH}_3)_2$; wherein $\text{—C(L}_1\text{)—R}_7^2$ taken together is: (1) $(\text{C}_4\text{-C}_7)\text{cycloalkyl}$ optionally substituted by 1 to 3 $(\text{C}_1\text{-C}_5)\text{alkyl}$; (2) 2-(2-furyl)ethyl; (3) 2-(3-thienyl)ethoxy; or (4) 3-thienyloxymethyl. (*Id.* at cols. 2:46-3:15.) ~~Treprostinil is the specific~~

IPR2020-00769

Formula I compound where $w = 1$; Y_1 is $-\text{CH}_2(\text{CH}_2)_m-$ and m is 1; M_1 is $\alpha\text{-OH}$; ($\beta\text{-R}_5$ or $\alpha\text{-R}_5$; $\beta\text{-OH}$, wherein R_5 is hydrogen; L_1 is $\alpha\text{-R}_3$; $\beta\text{-R}_4$; $\alpha\text{-R}^4$; $\beta\text{-R}_3$, or a mixture of $\alpha\text{-R}_3$; $\beta\text{-R}_4$ and $\alpha\text{-R}_4$; $\beta\text{-R}_3$, wherein R_3 and R_4 are hydrogen; and R_7 is $-\text{C}_p\text{H}_{2p}-\text{CH}_3$, wherein p is an integer from 1 to 5 inclusive ($p=3$).

The '066 patent discloses alkylating the treprostinil precursor (~~benzindene triol, a.k.a. treprostinil triol~~) with an alkylating agent and then hydrolyzing with a base. (*Id.* at col. 2:7-3:17.) The '066 patent further discloses contacting the product from the alkylation and hydrolysis steps with a base to form a salt (*e.g.* using the base diethanolamine to form treprostinil diethanolamine salt) of Formula I is shown below (~~where B is diethanolamine and where the other variables are the same as for the treprostinil-specific version of Formula I explained in the previous paragraph~~):¹



(*Id.* at col. 3:19-30.) The treprostinil salt can then be reacted with an acid to form the compound of [Formula 1](#) (treprostinil-specific [Formula I](#)). (*Id.* at col. 3:31-33.) [Formula 1](#) is at least 90.0%, 95.0%, or 99.0% pure. (*Id.* at col. 9:22-23.)

~~Formula I is a general formula, while Formula IV is specifically treprostinil. Formula IV, which is treprostinil, is disclosed to be at least 90.0%, 95.0%, or 99.0% pure. (*Id.* at col. 9:22-23.)~~

¹ Though the patent recites $-\text{C}(\text{L}_1)\text{-R}_2$, a POSA would understand this to be a typo. It should be $-\text{C}(\text{L}_1)\text{-R}_7$ because the patent teaches that L_1 and R_7 can be taken together to form a “cycloalkyl,” which a POSA would understand to be a ring. (Ex. 1001 at col. 3:2.)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.